Phio Pharmaceuticals, a clinical-stage biopharmaceutical company, announced that CEO Robert Bitterman will present an overview of its INTASYL siRNA gene silencing technology, including its lead candidate PH-762 for treating skin cancers, at the Renmark Virtual Non-Deal Roadshow on June 30, 2026. PH-762 is being developed as a non-surgical treatment targeting cutaneous carcinomas by silencing the PD-1 gene to enhance immune response against cancer cells. The presentation will include a live Q&A session and aims to highlight the unique approach of INTASYL in immuno-oncology. Investors can access the event online and a replay will be available afterward on Renmark's website.
A regional nonprofit health plan reduced its Transparency in Coverage machine-readable file (MRF) production time from 45 days to less than 24 hours by integrating TALON's platform directly with its claims administration system. This eliminated a com...
ASUS has introduced two new Chromebooks in the US market: the budget-friendly CM15 laptop and the versatile CM32 Detachable 2-in-1 device. Both run on the MediaTek Kompanio 540 processor, offer up to 12 hours of battery life, and feature military-gra...
Slate Medicines, a biotech firm focused on migraine treatments, has appointed Mark W. Hahn to its Board of Directors. Hahn brings over 25 years of experience in life sciences, including leading companies through financial milestones and FDA approvals...
The global clinical trials market is projected to grow from $135.51 billion in 2026 to $176.32 billion by 2030, at a CAGR of 6.8%. Growth is fueled by advances in AI-enabled trial design, decentralized and hybrid trial platforms, and increasing deman...
The global hybrid robots market is projected to grow from $5.68 billion in 2026 to $10.03 billion by 2030, with a CAGR of 15.3%. Growth is fueled by advances in AI, autonomous operations, and smart manufacturing, alongside rising demand for robots in...
